You are here: Welcome to the MPKB » Welcome to the MPKB » Diseases » Cancer
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Next revisionBoth sides next revision
home:diseases:cancer [05.16.2019] – [Recent research] sallieqhome:diseases:cancer [05.16.2019] – [Recent research] sallieq
Line 103: Line 103:
  
 Glioblastomas and malignant gliomas are the most common primary malignant brain tumors, with an annual incidence of 5.26 per 100,000 population. These tumors are typically associated with a dismal prognosis and poor quality of life. Only radiation exposure and certain genetic syndromes are well-defined risk factors for malignant glioma.   (({{pubmed>long:    24193082}}))  Glioblastomas and malignant gliomas are the most common primary malignant brain tumors, with an annual incidence of 5.26 per 100,000 population. These tumors are typically associated with a dismal prognosis and poor quality of life. Only radiation exposure and certain genetic syndromes are well-defined risk factors for malignant glioma.   (({{pubmed>long:    24193082}})) 
 +
 +This compound has antiproliferative and antimigratory effects in squamous cell carcinoma, glioblastoma, and breast cancer cell lines (({{pubmed>long:    31025400}}))
  
 Several researchers have highlighted a possible link between glioma and human cytomegalovirus (HCMV).  (({{pubmed>long:30888562}}))  Several researchers have highlighted a possible link between glioma and human cytomegalovirus (HCMV).  (({{pubmed>long:30888562}})) 
Line 372: Line 374:
  
 ===== Recent research ===== ===== Recent research =====
- 
  
 Paclitaxel Reduces Tumor Growth by Reprogramming Tumor-Associated Macrophages to an M1 Profile in a TLR4-Dependent Manner.  (({{pubmed>long:30104241}}))  Paclitaxel Reduces Tumor Growth by Reprogramming Tumor-Associated Macrophages to an M1 Profile in a TLR4-Dependent Manner.  (({{pubmed>long:30104241}})) 
- 
  
 {{section>:home:pathogenesis:innate_immunity#recent_research_into_valuable_proteins&noheader}} {{section>:home:pathogenesis:innate_immunity#recent_research_into_valuable_proteins&noheader}}
    
 Discovery of novel nonsteroidal VDR agonists with novel diarylmethane skeleton for the treatment of breast cancer. (({{pubmed>long:30579121}}))  Discovery of novel nonsteroidal VDR agonists with novel diarylmethane skeleton for the treatment of breast cancer. (({{pubmed>long:30579121}})) 
- 
-This compound has antiproliferative and antimigratory effects in squamous cell carcinoma, glioblastoma, and breast cancer cell lines (({{pubmed>long:    31025400}})) 
  
 Olmesartan and Bay11-7082 inhibit the MCF-7 cells growth indicating RAS and NF-kappaB pathway blockade lead to cytotoxicity and apoptosis induction against tumour cells. So ARBs and NF-kappaB pathway inhibitors could be considered as anticancer drugs in future.  (({{pubmed>long:26138656}})) Olmesartan and Bay11-7082 inhibit the MCF-7 cells growth indicating RAS and NF-kappaB pathway blockade lead to cytotoxicity and apoptosis induction against tumour cells. So ARBs and NF-kappaB pathway inhibitors could be considered as anticancer drugs in future.  (({{pubmed>long:26138656}}))
home/diseases/cancer.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.